High bad cholesterol is a risk factor for a common type of heart disease, yet approximately 40% of Americans living with high cholesterol don't know they have it and don't treat it1,2. Watch our Local ...
Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...
The spinout startup has turned to Wefunder for its pre-seed raise while also landing support from a main ecosystem partner.
Of the more than 30 antiseizure medications, three are seen as "pretty safe" in pregnancy, and another seven or so are known ...
Citryll has secured an oversubscribed Series B funding round, raising €85m ($89.8m) to advance the clinical development of ...
With an accuracy of 86%, the biomarker panel has the potential to be clinically useful in diagnosis, management, and ...
Lesley spent more than four years at Merck & Co. (NYSE: MRK) and about 19 years at the Genomics Institute of the Novartis ...
Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...
Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...
Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...